
usd apr pm et
summari rank one world largest pharmaceut compani offer wide rang
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
stock trade
biopharma revenu continu grow
yoy fuel doubl digit growth
global strong brand eliqui blood
newli launch drug
vyndaqel/vyndamax
treatment heart failur relat deposit
amyloid total sale
strong contribut biopharma
revenu could off-set
declin upjohn revenu total
revenu driven mainli increas
gener competit lyrica
lost product exclus start top-lin
revenu declin
adj ep fell yoy cut
ep estim assum
share repurchas in-lin pfe strategi
priorit dividend expect
growth trajectori improv follow
upjohn spin-off see revenu
guidanc mid-point rang
declin yoy improv
declin achiev given continu
strength biopharma brand oper
improv relat upjohn
recommend hold see tailwind
success newer treatment
mostli off-set next year gener
biosimilar competit older drug
accordingli expect yoy declin ep
growth still think enjoy
advantag smaller drug maker though
due larg portfolio diversifi across mani
therapeut area robust pipelin
expect larg drop-off lyrica enbrel
revenu continu due gener
biosimilar competit strong growth
exist oncolog drug total sale
yoy balanc
near-term long-term see even
promis oncolog drug come see
long-term growth improv provid
success complet upjohn spin-off
mid-year neg contribut
old brand remov mid/lat
stage pipelin ahead patent expir
cycl bring solid result
target price ep
estim histor forward price-to-earnings
averag see organ growth
improv risk view includ
pipelin setback unexpect gener
benefit divers portfolio drug eight
separ brand account annual
sale none contribut total
revenu differ brand drug develop
higher sale concentr key brand
howev still subject risk common
pharmaceut compani relat
expens uncertain clinic trial regulatori
hurdl well earlier-than-expect gener
biosimilar maker frequent challeng brand patent
valid court
may ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
execut vice-president chief
cfo evp global
chairman board
corpor overview one world largest biopharmaceut compani extens
oper drug develop manufactur market compani growth also augment
frequent acquisit largest market approxim sale
gener follow emerg market europ rest world
drug portfolio drug portfolio among divers global drug market view
compani top-sel drug prevnar famili vaccin sale total
ibranc sale total eliqui stroke embol grew
key drug experienc robust growth includ xeljanz
treatment arthriti ulcer coliti increas sale xtandi
use metastat non-metastat prostat cancer yoy top-sel drug lyrica
sale total treatment nerv pain epilept seizur saw declin sale yoy
due intens gener competit start juli patent expir
critic drug compani like consist success new drug growth
mode offset older drug declin sale due loss exclus competit new
improv treatment exampl type declin arthriti drug celebrex whose
sale peak around sinc fallen million patent
expir
next five year sever key patent expir occur hope off-set
growth newer drug patent expir includ chantix/champix sale sutent
sale ibranc sale vyndaqel/vyndamax sale
research develop effort continu off-set declin sale older drug
spend heavili research develop keep new drug come pipelin
global drug market spend increas sale
sale due higher spend licens agreement therachon akcea
new capabl autom invest immunolog diseas portfolio gene
march pipelin consist compound variou clinic trial phase
total phase final stage human clinic trial registr phase
fda approv final regulatori review drug market develop pipelin
includ potenti new treatment wide rang condit includ cancer obes arthriti heart
diseas diabet schizophrenia pain
market profil world-wide total prescript drug sale project grow compound annual
growth rate compound-annual-growth-rate period accord forecast evaluatepharma
key driver growth age develop popul especi babi
boomer age prime year health care need emerg market like see materi faster
growth prescript sale develop market howev due view
emerg market demand pharmaceut spur rise standard live global middl
class expand gain access advanc health care also develop market
govern increas health care spend
impact major develop announc plan spin
off-pat brand drug busi upjohn sale asset yet unnam new
compani viatri expect close upjohn sell mani well-known drug like viagra
lipitor major growth driver declin lose patent protect
sharehold viatri whose pro-forma free cash flow expect
around mean stake think good deal rid
declin busi upjohn sale yoy drag sale growth
process receiv sharehold get stake new compani also see deal
well-tim upjohn declin like acceler lyrica sale saw
roughli gener version enter market juli
curtail acquisit activ total two-year period
made major acquisit juli purchas array biopharma commerci stage
biopharmaceut focus discoveri develop commerci small molecul
medicin treat cancer diseas consequ share repurchas decreas
significantli yoy peak level
financi trend sale decreas repres three-year
compound annual growth rate despit contribut acquisit total
sinc start sale stagnant due mainli revenu declin off-pat drug
segment ebit margin increas primarili due
improv gross margin reduct sg
expens margin adjust ep risen
repres three-year compound-annual-growth-rate improv profit margin help ep
growth last three year note ep growth aid signific share buyback
made net repurchas billion worth share impact
new stock issuanc reduc share count process also paid
billion dividend three-year period
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli under-valued usd
bullish sinc april technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook sub-industri
next year neutral despit
defens natur expect sub-industri
continu see sluggish revenu earn
growth part shock
also lacklust new brand drug
develop above-averag patent expir
older brand
expect increas stockpil higher
demand pain killer fever reduc
respons provid revenu
benefit pharmaceut compani over-the-counter
franchis gener produc
counterbalanc decreas patient
hospit visit demand non-essenti
drug view term cost due
suppli chain disrupt delay caus
expect cost activ
pharmaceut ingredi increas
put pressur gross margin
particularli gener produc
hand expect sub-industri sg margin
trend expect decreas market
promot expens first half
year mani state start issu
stay-at-hom order march
recent slowdown novel drug approv
potenti new industri price regul
also expect major gener maker
continu struggl due lower-cost
follow banner year novel drug approv
signific slowdown occur
think weigh drug
maker revenu growth novel brand
drug enter market gener
competit often rival brand either
provid signific boost revenu
firm market total
number fda novel drug approv fell
versu expect mean less
revenu boost major brand drug
maker
addit fewer new brand enter
risk new price rule view kaiser
famili foundat poll indic
american feel drug cost unreason
think increas pressur drug
maker curtail usual price hike
politician enact polici lower drug
cost voter
balanc neg factor face
brand drug maker upcom period
low patent expir typic
biggest revenu headwind loss patent
protect open door gener
biosimilar competit base data
evaluatepharma annual global drug sale
risk expir patent averag
total forecast
drop fewer
patent cliff year ahead
major posit brand drug revenu
beyond brand firm make lion
share sub-industri market cap outlook
gener drug firm neg think
india-bas gener maker continu
take market share develop nation
firm due lower product cost
saw occur last year establish firm
like israel-bas teva saw sale
declin sale india-bas aurobindo
sun pharma grew yoy
think due cost advantag
rise broader composit
base index
five-year market price perform apr
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra keep hold opinion share pfizer inc
keep target roughli line histor peer averag
ep estim ep vs beat consensu
maintain ep estim rais sale
growth yoy similar rate seen full-year continu
balanc strong growth newer drug declin older one growth
quarter led prevnar pneumococc vaccin sale yoy
ibranc breast cancer yoy eliqui anti-clot yoy
lipitor blood pressur yoy xeljanz immunolog
yoy strong demand drug partial off-set lyrica neuropath
pain yoy ahead expect gener competit enbrel
immunolog yoy biosimilar competit think share
perform averag near term declin lyrica sale
upon gener entri limit ep growth /colin scarola
pm et cfra keep hold opinion share pfizer inc
keep target peer-averag ep estim
ep vs beat consensu lower ep
estim initi sale growth
yoy similar rate seen first nine month year led
robust sale growth ibranc breast cancer sale eliqui
anti-clot sale xeljanz immunolog sale three
drug account sale intern
expans new indic expect three continu robust
growth year forecast overal sale fall howev
due lyrica neurosci sale like declin precipit
gener competit begin june view long-term growth prospect
favor howev due attract pipelin promis phase
trial on-going potenti three major biosimilar approv
analyst research note compani news
pm et cfra keep hold opinion share pfizer inc
keep target ep estim
histor forward price-to-earnings averag continu see long-term growth improv
assum success complet upjohn spin-off take place
promis mid- late-stag pipelin ahead patent expir cycl
bring result cut ep estim
in-lin guidanc rang assum share repurchas
introduc ep post ep vs
estim consensu despit yoy growth
biopharma revenu top-lin declin yoy due contract
upjohn revenu driven increas gener competit lyrica
us due loss exclus see revenu guidanc
mid-point yoy achiev improv
declin given continu momentum biopharma oper improv
relat upjohn /sel hardi
pm et cfra keep hold opinion share pfizer inc
lower target ep estim
histor forward price-to-earnings averag see long-term growth improv
narrow focu biopharmaceut rais ep estim
maintain ep vs beat
consensu revenu grew yoy
exclud consum healthcar formerli revenu spun
off-pat upjohn segment current revenu spun
biopharma growth driven strong oncolog sale
total yoy lead drug ibranc continu gain market share
breast cancer market immunolog drug xeljanz yoy also drove
growth adjust ep fell yoy expect growth trajectori
improv late follow upjohn spin
promis oncolog portfolio becom significantli greater portion
total busi /colin scarola
pm et cfra keep hold opinion share pfizer inc
lower target ep estim --
histor forward price-to-earnings averag expect long-term organ revenu growth
improv narrow portfolio patent-protect drug ep
vs beat consensu maintain ep
estim total revenu fell yoy larg driven off-pat drug
segment upjohn revenu saw sale drop yoy biopharma
segment post solid growth yoy constant currenc cc howev
driven cc growth oncolog breast cancer drug ibranc
continu one strongest perform grow sale yoy cc
follow plan spin-out upjohn consum segment
expect fast-grow oncolog portfolio compris total
revenu today think improv long-term growth
remain neutral share see current price near fair valu
et cfra lower opinion share hold buy
keep target ep estim
unchang histor forward price-to-earnings averag due signific
litig risk competit lower-cost indian drug maker today
announc plan spin off-pat brand drug
busi upjohn asset yet unnam new compani
sharehold newco whose pro-forma free cash flow
around mean stake think well
deal better would earn
view given trail year downward trend
deal also increas resourc manag alleg price-fix litig risk
on-going market share loss india-bas competit view given
magnitud risk howev think long-term growth opportun
limit see share near fair valu adjust recommend
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
content includ rate credit-rel analys data valuat model softwar
applic output therefrom part thereof content may modifi
revers engin reproduc distribut form mean store
databas retriev system without prior written permiss cfra content shall
use unlaw unauthor purpos cfra third-parti provid
well director offic sharehold employe agent guarante
accuraci complet timeli avail content
past perform necessarili indic futur result
document may contain forward-look statement forecast forecast
reliabl indic futur perform
report intend constitut offer solicit buy sell
secur engag invest activ report inform purpos
recommend report made respect particular investor
type investor secur financi instrument strategi mention herein may
suitabl investor materi intend specif investor
take account investor particular invest object financi situat
need act recommend materi consid whether
suitabl particular circumst necessari seek profession advic
cfra may licens certain intellectu properti provid servic otherwis
busi relationship certain issuer secur subject cfra
research report includ exchange-trad invest whose invest object
substanti replic return proprietari index cfra case cfra
paid fee tie amount asset invest fund volum trade
activ fund invest fund may result cfra receiv compens
addit subscript fee compens servic render cfra
howev part cfra compens servic tie recommend
rate addit inform subject compani may avail upon request
cfra financi data provid global market intellig document contain
global industri classif standard gic develop and/or exclus
properti inc global market intellig gic servic mark
 global market intellig licens use cfra
disclaim notic
certain inform report provid global inc and/or affili
subsidiari collect global inform subject follow
disclaim notic copyright global market intellig affili
applic right reserv noth contain herein invest advic
refer particular invest secur credit rate observ
concern secur invest provid recommend buy
sell hold invest secur make invest decis may
contain inform obtain third parti includ rate credit rate
agenc reproduct distribut inform third parti content
form prohibit except prior written permiss global
relat third parti applic neither third parti provid guarante
accuraci complet timeli avail inform includ rate
respons error omiss neglig otherwis regardless
caus result obtain use inform content
includ rate credit rate statement opinion statement
fact recommend purchas hold sell secur address
suitabl secur suitabl secur invest purpos
reli invest advic
